Greenwich LifeSciences Advances FLAMINGO-01 Trial with FDA-Approved Commercial GP2 — Greenwich LifeSciences, Inc.

Event summary

Greenwich LifeSciences has begun treating patients in the FLAMINGO-01 trial with FDA-approved commercially manufactured GP2 vials.
All 40 US sites received the commercial GP2 vials within weeks of FDA approval, marking a critical milestone in the Phase III trial.
The company aims to expand manufacturing capacity to produce 500,000–1 million GP2 vials annually for potential commercial launch.
Preliminary data from the non-HLA-A*02 arm shows an approximately 80% reduction in recurrence rate after the Primary Immunization Series.

The big picture

Greenwich LifeSciences' transition to commercially manufactured GP2 vials represents a significant step toward potential commercialization of its immunotherapy for breast cancer recurrence prevention. The company's ability to secure FDA approval and rapidly distribute the vials highlights its operational readiness, while preliminary trial data suggests strong efficacy. Success in scaling manufacturing and securing international regulatory approvals will be critical for its long-term strategy.

What we're watching

Regulatory Approvals: Whether European, UK, and Canadian regulators will approve commercially manufactured GP2 for use in FLAMINGO-01 as quickly as the FDA.
Manufacturing Scaling: The pace at which Greenwich LifeSciences can scale up production to meet its target of 500,000–1 million vials annually.
Clinical Trial Outcomes: How the preliminary 80% reduction in recurrence rate in the non-HLA-A*02 arm will translate into final trial results and long-term efficacy.